Drug coated medical devices

Patent metadata

Field	Value
Publication number	US-10772993-B2
Application number	US-201815901711-A
Country	US
Kind code	B2
Filing date	Feb 21, 2018
Priority date	Feb 23, 2017
Publication date	Sep 15, 2020
Grant date	Sep 15, 2020

Abstract

A medical device includes a body defining an exterior surface, and a coating including a therapeutic agent-containing nanoparticle disposed on the exterior surface of the medical device. The nanoparticle may include a brush-arm star polymer. The therapeutic agent may be paclitaxel.

First claim

What is claimed is:

1. A medical device comprising:
a body having an exterior surface; and
a coating disposed on the exterior surface of the body, the coating comprising a therapeutic agent-containing nanoparticle, wherein the nanoparticle comprises a brush-arm star polymer, wherein the therapeutic agent of the therapeutic agent-nanoparticle comprises an antiproliferative agent, and wherein the coating further comprises a second therapeutic agent that is not associated with the nanoparticle, wherein the second therapeutic agent is an anti-proliferative agent, wherein the therapeutic agent of the therapeutic agent-nanoparticle and the second therapeutic agent are the same,
wherein the coating is configured such that, upon implantation of the device at a target location or upon release of the coating from the device to tissue at the target location, substantial uptake of the second therapeutic agent occurs prior to substantial uptake of the therapeutic agent of the therapeutic agent-nanoparticle.

2. The medical device of claim 1 , wherein the nanoparticle comprises a cleavable linker attaching the therapeutic agent to the nanoparticle.

3. The medical device of claim 2 , wherein the cleavable linker is a linker cleavable by hydrolysis.

4. The medical device of claim 3 , wherein the cleavage linker comprises an ester bond.

5. The medical device of claim 1 , wherein the nanoparticle is formed by polymerization of one or more macro-monomers, at least one of which comprises the therapeutic agent, to form bottle-brush polymers having a living chain end, and connecting the bottle-brush polymers having a living chain end with a cross-linker to form the brush-arm star polymer nanoparticle.

6. The medical device of claim 5 , wherein the cross-linker comprises a cleavable linker.

7. The medical device of claim 6 , wherein the cleavable linker is a linker cleavable by hydrolysis.

8. The medical device of claim 7 , wherein the cleavage linker comprises an ester bond.

9. The medical device of claim 1 , wherein the therapeutic agent is paclitaxel.

10. The medical device of claim 1 , wherein the coating further comprises urea.

11. The medical device of claim 1 , wherein the body comprises a stent.

12. The medical device of claim 1 , wherein the body comprises an inflatable balloon defining an interior surface, wherein the interior surface defines an interior space.

13. The medical device of claim 12 , further comprising a catheter comprising a lumen in fluid communication with the interior space of the inflatable balloon.

14. A method comprising:
providing a medical device according to claim 1 ;
inserting the medical device to the target location of a patient; and
contacting the medical device to tissue at the target location,
wherein contacting the medical device to the tissue causes the therapeutic agent-containing nanoparticle to be transferred to the tissue.

15. The method of claim 14 , wherein the tissue of the patient to which the nanoparticle is transferred is a wall of an artery.

16. The method of claim 14 , wherein the target location is a location of a narrowed artery.

17. The medical device of claim 1 , wherein the coating further comprises a second therapeutic agent-containing nanoparticle comprising an anti-inflammatory steroid and a brush-arm star polymer.

18. The medical device of claim 9 , wherein the coating further comprises a second therapeutic agent-containing nanoparticle comprising an anti-inflammatory steroid and a brush-arm star polymer.

19. The medical device of claim 18 , wherein the anti-inflammatory steroid is dexamethasone, dexamethasone sodium phosphate, or dexamethasone acetate.

20. The medical device of claim 1 , wherein substantial uptake of the therapeutic agent of the therapeutic agent-containing nanoparticle is delayed until the second therapeutic agent declines to approach tissue concentrations that are near an effective concentration of the therapeutic agent to maintain an effective concentration of the therapeutic agent in the target tissue for an extended time.

Assignees

• Medtronic Vascular Inc

Inventors

• Raina Shashank
• Kantor John
• Peterson Susan

Classifications

• A61L31/16 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L2300/80

  characterised by a special chemical form · CPC title

• A61L2300/602

  Type of release, e.g. controlled, sustained, slow · CPC title

• A61L29/06

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

• A61L2400/18

  Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment · CPC title